Press Releases & Updates
September 05, 2023
Advantx Pharmaceuticals Selected to Present it’s World-Class Sigma Platform at PAINWeek
Advantx Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing advanced disease-modifying therapies based on Sigma receptors, announced today that it has been selected to present at the prestigious PAINWeek conference, September 5th – 8th in Las Vegas. This will be the company’s first time showcasing their platform to the U.S. Conference Community, after presenting at Roma Pain Days in Italy and other various conferences in Mexico and Tunisia.
More Info: 230905 Advantx PAINWeek
The Emerging Role of Sigma Receptors in Pain Medicine
By Joseph Pergolizzi Jr and Giustino Varrassi Excerpt from the article published in Cureus 15(7): e42626. July 28, 2023, doi:10.7759/cureus.42626 Abstract Sigma receptors are protein chaperones with the unexpected characteristic of being activated by ligand binding. As such, they represent intriguing new targets for potential drug development. As a protein chaperone, these “receptors” escort proteins from […]
The Sigma Enigma: A Narrative Review of Sigma Receptors
By Joseph Pergolizzi, Giustino Varrassi, Mark Coleman, Frank Breve, Dana K. Christo, Paul J. Christo, and Charbel Moussa Excerpt from the article published in Cureus 15(3): e35756. March 04, 2023; doi: 10.7759/cureus.35756 Abstract The sigma-1 and sigma-2 receptors were first discovered in the 1960s and were thought to be a form of opioid receptors initially. […]